Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tanya Barauskas Dorff

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?Tanya Barauskas Dorff, Mitchell E Gross
Journal of Clinical Medicine|March 11, 2023
Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy ApproachesTanya Barauskas Dorff, Saro Kasparian, Natasha Garg, et al.
Prostate Cancer|January 7, 2026
Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-TNeal D Shore, Emmanuel S Antonarakis, Jason Hafron, et al.
European Urology Focus|December 7, 2025
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 MutationsHeather H Cheng, Sam Callis, Evan Y Yu, et al.
Cancer|December 1, 2024
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024Alan H Bryce, Neeraj Agarwal, Himisha Beltran, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?Tanya Barauskas Dorff, Mitchell E Gross
Journal of Clinical Medicine|March 11, 2023
Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy ApproachesTanya Barauskas Dorff, Saro Kasparian, Natasha Garg, et al.
Prostate Cancer|January 7, 2026
Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-TNeal D Shore, Emmanuel S Antonarakis, Jason Hafron, et al.
European Urology Focus|December 7, 2025
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 MutationsHeather H Cheng, Sam Callis, Evan Y Yu, et al.
Cancer|December 1, 2024
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024Alan H Bryce, Neeraj Agarwal, Himisha Beltran, et al.
Pageof 1